ArticleOncotarget2017

MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma.

Alexandre Bozec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.